Impax Large Cap Fund is a core US equities strategy that invests in companies with attractive valuations and sustainability ...

Amneal Pharmaceuticals and Impax Laboratories will combine to form the fifth largest generics business in the country, based on revenue. Here are four things to know about the deal. 1. Under the ...

(Reuters) - Amneal Pharmaceuticals LLC is buying fellow generics drug maker Impax Laboratories Inc (IPXL.O) in an all-stock deal as a bulwark against a tough drug pricing environment. The deal comes ...

Analysts have cut their fair value estimate for Impax Asset Management Group from £2.26 to £1.88, reducing the implied upside in their model. This shift reflects a more cautious analyst stance on ...

Deal follows jury's rejection of claims against co-defendant Endo Plaintiffs' lawyers to seek up to $58 million in legal fees (Reuters) - Impax Laboratories on Tuesday said it had agreed to pay, opens ...

In response to receiving a double dose of good news from the Food and Drug Administration (FDA) and some bullish commentary from Wall Street, shares of Impax Laboratories (NASDAQ: IPXL), a maker of ...

Impax has announced several changes within its listed equity team, including developments that affect its strategies focused on environmental markets. David Winborne will step back from his ...

Impax Laboratories (NASDAQ: IPXL) closed up 10% on Thursday after jumping 9.6% yesterday following its second-quarter earnings report. Today's move seems to be a continuation of yesterday's jump, ...

HAYWARD, Calif. & CUPERTINO, Calif.--(BUSINESS WIRE)-- Impax Laboratories, Inc.(NASDAQ:IPXL) and DURECT Corporation (Nasdaq:DRRX) announced today that they have entered into an agreement granting ...

Stop me if you’ve heard this one before: the FTC is suing pharmaceutical manufacturers Endo and Impax over an alleged “reverse payment” agreement to reduce competition in the market for Opana ER, an ...

BOSTON (Reuters) - Impax Laboratories Inc has agreed to pay $20 million to consumers and insurers to resolve claims that the drugmaker entered an anticompetitive deal to delay launching a generic, ...